- The
company is working to be a major provider of premier CDB products
- ETST’S
three subsidiaries focus on developing its role as a global leader in the
CBD space
- ETST
is forward-thinking – centering on the science, research and studies of
its high-grade hemp CBD oil
Based in Doral, Florida, Earth Science Tech, Inc. (OTC:
ETST) is a biotechnology company with three wholly owned subsidiaries. Through
these, it operates in the fields of hemp cannabinoid (CBD), nutraceutical,
pharmaceutical and medical device research and development. CBD offered by the
company is in the form of vitamins, minerals, herbs, botanicals, personal care
products, homeopathies, functional foods and other products.
CBD is a naturally occurring constituent of industrial hemp
oil. ETST is advancing its efforts to be a major provider of premier CDB
products. Business Insider recently noted (http://ibn.fm/z2Jqd) that “CBD is estimated to make up a
roughly $1 billion industry, but the recent federal approval could make it even
more lucrative by jump-starting demand for CBD-based products.”
ETST’s wholly owned subsidiaries are Earth Science
Pharmaceutical Inc., Cannabis Therapeutics Inc., and KannaBidioiD, Inc. These
subsidiaries center on developing ETST’s role as an international leader in the
CBD space. They also focus on expanding the company’s work in the
pharmaceutical and medical device sectors.
Earth Science Pharmaceutical’s mission is to develop low
cost, noninvasive diagnostic tools, medical devices, testing processes and
vaccines for sexually transmitted infections and/or diseases. Cannabis
Therapeutics’ emphasis is on developing new, pioneering, cannabinoid-based
pharmaceutical and nutraceutical products. KannaBidioiD (KBD) focuses on
products for the recreational cannabis space.
Furthermore, ETST has its Canadian subsidiary, Canna Inno Laboratories, Inc. (Montreal, Québec), which it acquired last year. The company established this subsidiary to give it a position in the province and to provide it with access to government grants.
ETST’s three-year strategic plan, created in 2017, includes
expansion into Canada. The company recently attended the largest Cannabis Expo
in Canada, the Lift and Co. Expo.
In a news release, Dr. Michel Aubé, ETST’S chief executive
officer and chief scientific officer, said, “I met many leaders in the Canadian
medical cannabis industry, as well as future leaders in the burgeoning legal
recreational cannabis industry and visionary lenders who are active in
financing cannabis industry growth. We will pursue some of these new
relationships in the coming months.”
ETST is now developing three new CBD formulas that are under
a provisory patent. One CBD formula product is a neuron protector and the other
is a breast protector. The third CBD formula is a new kind of superfood with
distinctive organoleptic properties.
ETST is moving forward concentrating on the science,
research and study of its high-grade hemp CBD oil as a nutraceutical and
dietary supplement. In addition, the company has completed the set-up of its
scientific advisory council with a team of recognized scientists. Furthermore,
it is making its entry into the medical devices market via collaborative
partnerships. ETST’s management team, with decades of experience in the
nutraceutical, dietary supplement and life sciences sectors, is steering the
company in an exciting direction.
For more information, visit the company’s website at www.EarthScienceTech.com
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
